DESCANSO, a Mental Health Intervention for Depression, Insomnia, and Fatigue Symptoms in Latino People With Cancer
Part of paid clinical trials in Basking Ridge, New Jersey.
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Study ID
- NCT07225088
- Status
- Recruiting
Conditions
- Solid Tumor
- Solid Tumor, Adult
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Accepted
Interventions
- DESCANSO/Depresión/Depressed Mood, Cansancio/Fatigue, and Sueño/Sleep; Rest in English — BEHAVIORALDESCANSO (Depresión/Depressed Mood, Cansancio/Fatigue, and Sueño/Sleep; Rest in English)
Study Details
The purpose of this study is to improve ways of providing mental health support to Spanish-speaking Latino participants who have cancer and experience depression, insomnia, and fatigue. Investigators will test a special mental health intervention called DESCANSO/REST (Depresión/Depressed Mood, Cansancio/Fatigue, and Sueño/Sleep). The intervention can be delivered through telehealth.
Key Dates
- Start date
- Jan 23, 2026
- Status verified
- Jan 2026
- Primary completion
- Apr 30, 2029
- Completion
- Apr 30, 2029
Study Design
- Enrollment
- 125 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- SUPPORTIVE_CARE
Arms
- Experimental: Experimental Intervention: DESCANSOParticipants will receive DESCANSO (Depresión/Depressed Mood, Cansancio/Fatigue, and Sueño/Sleep; Rest in English)
- No Intervention: Control Intervention: Enhanced Usual CareParticipants will receive Enhanced Usual Care
Primary Outcome Measure
Number of participants who complete at least 5 DESCANSO sessions [ Time Frame: Up to 1 year ]
Central Contacts
- Rosario Costas Muniz, PhD646-888-8062
- Victoria Blinder, MD646-888-4808
Locations (7)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Memorial Sloan Kettering Cancer Center Basking Ridge (Limited Protocol Activities) | Basking Ridge | New Jersey | 07920 | Rosario Costas Muniz, PhD 646-888-8062 |
| Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown | New Jersey | 07748 | Rosario Costas Muniz, PhD 646-888-8062 |
| Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale | New Jersey | 07645 | Rosario Costas Muniz, PhD 646-888-8062 |
| Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity) | Commack | New York | 11725 | Rosario Costas Muniz, PhD 646-888-8062 |
| Memorial Sloan Kettering Westchester (Limited Protocol Activities) | Harrison | New York | 10604 | Rosario Costas Muniz, PhD 646-888-8062 |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | Rosario Costas Muniz, PhD 646-888-8062 Rosario Costas Muniz, PhD (PRINCIPAL_INVESTIGATOR) |
| Memorial Sloan Kettering Nassau (Limited Protocol Activites) | Rockville Centre | New York | 11553 | Rosario Costas Muniz, PhD 646-888-8062 |
Find similar trials in Basking Ridge, NJ
By research site
Memorial Sloan Kettering Cancer Center Basking Ridge (Limited Protocol Activities)· Basking Ridge, NJMemorial Sloan Kettering Monmouth (Limited Protocol Activities)· Middletown, NJMemorial Sloan Kettering Bergen (Limited Protocol Activities)· Montvale, NJMemorial Sloan Kettering Suffolk-Commack (Limited protocol activity)· Commack, NYMemorial Sloan Kettering Westchester (Limited Protocol Activities)· Harrison, NYMemorial Sloan Kettering Cancer Center· New York, NY
Related Studies
- A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)PHASE1/PHASE2 · Recruiting · Merck Sharp & Dohme LLC · Aurora, Colorado
- Umbilical Cord Blood Transplantation From Unrelated DonorsRecruiting · University of Rochester · Rochester, New York
- Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With SarcomaPHASE1/PHASE2 · Recruiting · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · St. Petersburg, Florida
- ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid TumorsPHASE1/PHASE2 · Recruiting · Immatics US, Inc. · Stanford, California